Last update 08 May 2025

Recombinant Epstein-Barr Virus Vaccine(The Chinese University of Hong Kong)

Overview

Basic Info

Drug Type
Therapeutic vaccine
Synonyms
MVA EBNA1/LMP2 vaccine(The Chinese University of Hong Kong)
Target-
Action
stimulants
Mechanism
Immunostimulants
Therapeutic Areas
NeoplasmsInfectious DiseasesMouth and Tooth Diseases+ [1]
Active Indication-
Inactive Indication
Epstein-Barr Virus InfectionsNasopharyngeal Cancer, Recurrent
Originator Organization
The Chinese University of Hong KongThe Chinese University of Hong Kong
Active Organization-
Inactive Organization
The Chinese University of Hong KongThe Chinese University of Hong Kong
License Organization-
Drug Highest PhasePendingPhase 2
First Approval Date-
Regulation-
Login to view timeline

Related

2
Clinical Trials associated with Recombinant Epstein-Barr Virus Vaccine(The Chinese University of Hong Kong)
NCT01094405
/ CompletedPhase 2IIT
Efficacy of Recombinant Epstein-Barr Virus (EBV) Vaccine in Patients With Nasopharyngeal Cancer Who Had Residual EBV DNA Load After Conventional Therapy
NCT01147991
/ CompletedPhase 1IIT
A Phase I, Dose Escalation Trial of Recombinant Modified Vaccinia Ankara (MVA)-Based Vaccine Encoding Epstein-Barr Virus Target Antigens
100 Clinical Results associated with Recombinant Epstein-Barr Virus Vaccine(The Chinese University of Hong Kong)
Login to view more data
100 Translational Medicine associated with Recombinant Epstein-Barr Virus Vaccine(The Chinese University of Hong Kong)
Login to view more data
100 Patents (Medical) associated with Recombinant Epstein-Barr Virus Vaccine(The Chinese University of Hong Kong)
Login to view more data
100 Deals associated with Recombinant Epstein-Barr Virus Vaccine(The Chinese University of Hong Kong)
Login to view more data

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Epstein-Barr Virus InfectionsPhase 2
Hong Kong
The Chinese University of Hong KongThe Chinese University of Hong Kong
31 Mar 2010
Nasopharyngeal Cancer, RecurrentPhase 2
Hong Kong
The Chinese University of Hong KongThe Chinese University of Hong Kong
31 Mar 2010
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date

No Data

Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
login
or
view full example data
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
login
or
view full example data
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
login
or
view full example data
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
login
or
view full example data
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
login
or
view full example data
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
login
or
view full example data
Understand key drug designations in just a few clicks with Synapse.
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free